NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets cut their price target on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

NBY stock opened at $0.62 on Friday. The company has a 50 day moving average price of $0.63 and a 200 day moving average price of $0.90. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08. The stock has a market capitalization of $3.03 million, a PE ratio of -0.01 and a beta of 0.65.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.